Parmax Pharma Share Price
Start SIP in Parmax Pharma
Start SIPParmax Pharma Performance
Day Range
- Low 0
- High 0
52 Week Range
- Low 0
- High 0
- Open Price0
- Previous Close0
- Volume
Parmax Pharma Investment Rating
-
Master Rating:
-
Parmax Pharma has an operating revenue of Rs. 17.47 Cr. on a trailing 12-month basis. An annual revenue de-growth of -28% needs improvement, Pre-tax margin of -51% needs improvement, ROE of -5458% is poor and needs improvement. The company has a high debt to equity of 5607%, which can be a reason to worry. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -11% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 32 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 53 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 8 | 4 | 1 | 4 | 1 | 6 |
| Operating Expenses Qtr Cr | 7 | 5 | 2 | 5 | 2 | 6 |
| Operating Profit Qtr Cr | 1 | -1 | -1 | -1 | -1 | 1 |
| Depreciation Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit Qtr Cr | 0 | -1 | -2 | -1 | -1 | 0 |
Parmax Pharma Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹34.67
- 50 Day
- ₹34.36
- 100 Day
- ₹33.42
- 200 Day
- ₹32.60
- 20 Day
- ₹34.38
- 50 Day
- ₹34.95
- 100 Day
- ₹32.74
- 200 Day
- ₹32.10
Parmax Pharma Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 35.81 |
| Second Resistance | 36.58 |
| Third Resistance | 37.98 |
| RSI | 51.39 |
| MFI | 64.87 |
| MACD Single Line | -0.11 |
| MACD | -0.19 |
| Support | |
|---|---|
| First Support | 33.64 |
| Second Support | 32.24 |
| Third Supoort | 31.47 |
Parmax Pharma Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 2,044 | 204,400 | 100 |
| Week | 1,140 | 114,000 | 100 |
| 1 Month | 1,330 | 132,971 | 100 |
| 6 Month | 3,425 | 242,827 | 70.9 |
Parmax Pharma Result Highlights
Parmax Pharma Synopsis
BSE-Medical-Diversified
Parmax Pharma is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 15.42 Cr. and Equity Capital is Rs. 4.45 Cr. for the Year ended 31/03/2023. Parmax Pharma Ltd. is a Public Limited Listed company incorporated on 02/11/1994 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24231GJ1994PLC023504 and registration number is 023504.| Market Cap | 13 |
| Sales | 17 |
| Shares in Float | 0.26 |
| No of funds | |
| Yield |
| Book Value | 146.04 |
| U/D Vol ratio | 1.9 |
| LTDebt / Equity | 5607 |
| Alpha | 0.07 |
| Beta | 0.51 |
Parmax Pharma Shareholding Pattern
| Owner Name | Jun-24 | Mar-24 | Dec-23 | Sep-23 |
|---|---|---|---|---|
| Promoters | 30.8% | 30.83% | 30.8% | 30.8% |
| Individual Investors | 65.78% | 65.34% | 65.43% | 65.43% |
| Others | 3.42% | 3.83% | 3.77% | 3.77% |
Parmax Pharma Management
| Name | Designation |
|---|---|
| Dr. Umang Alkesh Gosalia | Managing Director |
| Ms. Ami R Shah | Independent Director |
| Mr. Nikhil S Uchat | Independent Director |
Parmax Pharma Forecast
Price Estimates
Parmax Pharma Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2024-08-14 | Quarterly Results | |
| 2024-05-30 | Audited Results | (Revised) |
| 2024-02-14 | Quarterly Results | |
| 2023-11-10 | Quarterly Results | |
| 2023-08-14 | Quarterly Results |
Parmax Pharma FAQs
What is Share Price of Parmax Pharma ?
Parmax Pharma share price is ₹35 As on 08 September, 2024 | 09:47
What is the Market Cap of Parmax Pharma ?
The Market Cap of Parmax Pharma is ₹13.2 Cr As on 08 September, 2024 | 09:47
What is the P/E ratio of Parmax Pharma ?
The P/E ratio of Parmax Pharma is -2.9 As on 08 September, 2024 | 09:47
What is the PB ratio of Parmax Pharma ?
The PB ratio of Parmax Pharma is 125.2 As on 08 September, 2024 | 09:47